BeOne Medicines AG (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 379.35B +37.8% |
| Revenue (ttm) | 50.58B +29.6% |
| Net Income | 8.00B +1,387.8% |
| EPS | 5.25 +1,353.4% |
| Shares Out | n/a |
| PE Ratio | 48.00 |
| Forward PE | 43.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,724,274 |
| Open | 253.40 |
| Previous Close | 252.20 |
| Day's Range | 248.80 - 254.80 |
| 52-Week Range | 153.00 - 267.00 |
| Beta | 0.63 |
| Analysts | Strong Buy |
| Price Target | 278.67 (+10.67%) |
| Earnings Date | Nov 5, 2026 |
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
Analyst Summary
According to 16 analysts, the average rating for 6160 stock is "Strong Buy." The 12-month stock price target is $278.67, which is an increase of 10.67% from the latest price.
News
BeOne Medicines price target raised to $477 from $454 at TD Cowen
TD Cowen raised the firm’s price target on BeOne Medicines (ONC) to $477 from $454 and keeps a Buy rating on the shares. The firm updated its model following beat…
BeOne Medicines price target raised to $465 from $425 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on BeOne Medicines (ONC) to $465 from $425 and keeps an Overweight rating on the shares.
BeOne Medicines Q3 Earnings Call Highlights
BeOne Medicines NASDAQ: ONC raised its 2026 revenue and operating income forecasts after third-quarter sales of its cancer drug BRUKINSA topped $1 billion in the United States for the first time.
BeOne Medicines price target raised to $448 from $420 at Truist
Truist raised the firm’s price target on BeOne Medicines (ONC) to $448 from $420 and keeps a Buy rating on the shares. The company’s Q3 earnings and the firm’s subsequent…
BeOne Medicines price target raised to $463 from $405 at Citizens
Citizens raised the firm’s price target on BeOne Medicines (ONC) to $463 from $405 and keeps an Outperform rating on the shares. BeOne raised full-year guidance again on strong performance,…
BeOne Medicines price target raised to $446 from $415 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on BeOne Medicines (ONC) to $446 from $415 and keeps an Overweight rating on the shares following the “beat and raise”…
Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key m...
BeOne Medicines (ONC) Q3 2026 Earnings Call Transcript
Solid tumor pipeline nears key trials as guidance rises on hematology strength.
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone.
BeOne Medicines AG Earnings Call Transcript: Q3 2026
Q3 revenue rose 33% to $1.9B, with BRUKINSA at $1.4B and operating income up 157%. 2026 guidance increased, while investment in a broad late-stage pipeline is expected to temper 2027 margin expansion.
BeOne Medicines AG Earnings release: Q3 2026
BeOne Medicines AG released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
BeOne Medicines AG Quarterly report: Q3 2026
BeOne Medicines AG has published its Q3 2026 quarterly earnings report on November 5, 2026.
BeOne Medicines AG Slides: Q3 2026
BeOne Medicines AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
BeOne Medicines AG Prepared remarks: Q3 2026
BeOne Medicines AG filed a regulatory document on November 5, 2026 disclosing important business information.
BeOne Medicines AG Announces Third Quarter 2026 Financial Results and Raised Full Year Guidance
BeOne Medicines AG reported total global revenues of $1.9 billion for the third quarter of 2026, representing an increase of 34% from the prior year. Global sales of BRUKINSA reached $1.4 billion, an ...
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates fr...
BeOne Medicines announces FDA priority review for BRUKINSA combination
BeOne Medicines (ONC) announced that the U.S. Food and Drug Administration has accepted and granted Priority Review to the supplemental New Drug Application for BRUKINSA in combination with rituximab ...
U.S. FDA Grants Priority Review to BeOne Medicines' BRUKINSA Combination in First-Line Mantle Cell Lymphoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's poten...
BeOne Medicines to Present at the Jefferies Global Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Globa...
BeOne Medicines presents new data across solid tumor disease areas at ESMO 2026
BeOne Medicines (ONC) announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology, ESMO, Congre...
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve...
BeOne Medicines reports ‘sustained survival benefit’ with TEVIMBRA-ZIIHERA combo
BeOne Medicines (ONC) announced new survival results from the planned second interim analysis and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA ...
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned seco...
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Th...